Swiss National Bank increased its holdings in shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) by 32.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 58,600 shares of the biopharmaceutical company’s stock after acquiring an additional 14,300 shares during the quarter. Swiss National Bank owned about 0.14% of Bellicum Pharmaceuticals worth $432,000 as of its most recent SEC filing.
Several other hedge funds have also bought and sold shares of BLCM. Schwab Charles Investment Management Inc. lifted its holdings in shares of Bellicum Pharmaceuticals by 81.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 232,703 shares of the biopharmaceutical company’s stock valued at $1,718,000 after purchasing an additional 104,179 shares in the last quarter. Bellevue Group AG bought a new position in shares of Bellicum Pharmaceuticals in the second quarter valued at approximately $664,000. ARK Investment Management LLC bought a new position in shares of Bellicum Pharmaceuticals in the second quarter valued at approximately $2,094,000. Bank of New York Mellon Corp lifted its holdings in shares of Bellicum Pharmaceuticals by 36.7% in the second quarter. Bank of New York Mellon Corp now owns 149,652 shares of the biopharmaceutical company’s stock valued at $1,104,000 after purchasing an additional 40,212 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of Bellicum Pharmaceuticals by 458.9% in the second quarter. Rhumbline Advisers now owns 138,493 shares of the biopharmaceutical company’s stock valued at $1,022,000 after purchasing an additional 113,715 shares in the last quarter. 59.42% of the stock is currently owned by institutional investors and hedge funds.
A number of research firms have recently weighed in on BLCM. ValuEngine upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 10th. BidaskClub lowered Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, June 21st. Citigroup dropped their target price on Bellicum Pharmaceuticals from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Thursday, August 9th. Finally, Cantor Fitzgerald set a $18.00 target price on Bellicum Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 7th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $14.17.
In other Bellicum Pharmaceuticals news, CTO David M. Spencer sold 10,000 shares of the firm’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $7.04, for a total value of $70,400.00. Following the completion of the sale, the chief technology officer now directly owns 89,939 shares of the company’s stock, valued at $633,170.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider David M. Spencer sold 40,000 shares of Bellicum Pharmaceuticals stock in a transaction on Wednesday, July 18th. The shares were sold at an average price of $7.63, for a total value of $305,200.00. Following the completion of the transaction, the insider now owns 99,939 shares of the company’s stock, valued at $762,534.57. The disclosure for this sale can be found here. Company insiders own 9.84% of the company’s stock.
Bellicum Pharmaceuticals stock traded down $0.09 during mid-day trading on Friday, reaching $5.20. 313,206 shares of the company’s stock were exchanged, compared to its average volume of 755,419. The company has a current ratio of 10.24, a quick ratio of 10.24 and a debt-to-equity ratio of 0.32. Bellicum Pharmaceuticals Inc has a one year low of $5.02 and a one year high of $10.74. The firm has a market capitalization of $267.03 million, a P/E ratio of -1.83 and a beta of 0.56.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.05). The business had revenue of $0.36 million during the quarter, compared to analyst estimates of $0.08 million. Analysts predict that Bellicum Pharmaceuticals Inc will post -2.37 EPS for the current fiscal year.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
Featured Story: What is a Tariff?
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.